In addition, breast cancer had a high correlation with ARONJ; however, in patients with metastases, intravenous BPs or RANKL inhibitors were used, which reduced bone metabolism and turnover and resulted in ARONJ. This evidence concerns the gene TNFSF11 and breast cancer.